Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans

Gefapixant (MK‐7264) is a first‐in‐class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non‐clinical studies, gefapixant was eliminated primarily by renal excretion of the pare...

Descripción completa

Detalles Bibliográficos
Autores principales: Nussbaum, Jesse C., Hussain, Azher, Ma, Bennett, Min, K. Chris, Chen, Qing, Tomek, Charles, Iwamoto, Marian, Stoch, S. Aubrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929362/
https://www.ncbi.nlm.nih.gov/pubmed/35106949
http://dx.doi.org/10.1002/prp2.924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929362/
https://www.ncbi.nlm.nih.gov/pubmed/35106949
http://dx.doi.org/10.1002/prp2.924

Ejemplares similares